© 2023 Intra-Cellular Therapies Inc. All rights reserved.
Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
Intra-Cellular Therapies Announces Favorable Safety Profile for ITI-214 in a Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease
October 23, 2018 at 7:00 AM EDT
Results show ITI-214 is associated with clinical signs consistent with improvements in motor symptoms and dyskinesias
The primary objective of this Phase 1/2, randomized, double-blind, placebo-controlled, multiple ascending dose cohort study was to evaluate the safety and tolerability of ITI-214 and to explore the potential for ITI-214 to treat both motor and non-motor symptoms associated with PD. Topline results demonstrate ITI-214 was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. The trial was conducted at the
“In this trial, once-daily ITI-214 for 7 days was shown to be safe and generally well tolerated across a broad range of doses from 1 mg to 90 mg in subjects currently maintained on dopamine replacement therapy,” commented Dr.
“Improvement in motor symptoms and reduction in motor complications (e.g., reduced dyskinesias) were noted with ITI-214 treatment,” said Dr.
“ITI-214 is a potent and selective phosphodiesterase 1 (PDE1) inhibitor and represents a novel approach with the potential to address unmet needs in the treatment of Parkinson’s disease for improved motor control and potential disease modification. Following the safety and tolerability results in healthy volunteers in our Phase 1 program, we are pleased to announce the favorable safety profile of ITI-214 in patients with Parkinson’s disease,” said Dr.
About the ITI-214-105 Phase 1/2 Clinical Trial
This was a Phase 1/2 randomized, double-blind, placebo-controlled, multiple ascending dose cohort study of ITI-214 in 40 patients with idiopathic PD. Patients with mild to moderate PD (Hoehn and Yahr staging score of 1-3 assessed in the “On” state) who were maintained on stable PD therapy were randomly assigned to placebo or ITI-214 1, 3, 10, 30, and 90 mg administered orally once daily for 7 days. The primary objective was to evaluate the safety and tolerability of ITI-214 in this patient population. All randomized subjects completed the study. No serious adverse events were reported in the trial, and no clinically significant effects of ITI-214 compared to placebo were observed on vital signs, and cardiovascular or laboratory parameters.
The efficacy of ITI-214 in improving motor and non-motor symptoms of PD was measured using multiple scales, providing input from both subjects and site raters. Motor performance was improved in the “On” state by ITI-214 relative to placebo treatment as assessed by the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). ITI-214 reduced scores on the MDS-UPDRS total scale and 2 subscales: Part III - clinician ratings of the motor manifestations of PD, and Part IV- motor complications including dyskinesias. In addition, ITI-214 reduced dyskinesia symptoms as measured by the Unified Dyskinesia Rating Score (UDysRS) and increased total On time and On time without dyskinesias as rated by subjects using the Hauser Patient Motor Diary.
Additional results of study ITI-214-105 will be presented at future meetings.
About ITI-214
ITI-214 is a potent and selective phosphodiesterase 1 (PDE1) inhibitor. As the clinical lead compound in the Company’s PDE1 portfolio, ITI-214, has been found to be generally well tolerated with a favorable safety profile in four Phase 1 clinical trials, in healthy volunteers. Inhibitors of PDE1 block the breakdown of cyclic nucleotides (cAMP, cGMP), potentiating downstream intracellular signaling. The PDE1 enzyme is highly active in pathological or disease states, and our PDE1 inhibitors are designed to reestablish normal function in these disease states. PDE1 inhibitors have minimal effect on normal function, only acting when cells in the nervous system are stimulated. These "on-demand" effects make this an exciting and novel approach for the treatment of disease. In animal models, inhibition of PDE1 has been shown to reduce neuroinflammation and to reduce neurodegeneration. The mechanism of action of PDE1 inhibitors suggests therapeutic potential across a variety of neurological and cardiovascular diseases.
Preclinical studies suggest that PDE1 inhibitors potentiate L-DOPA and other dopamine replacement therapies yielding improved motor symptom control while reducing adverse motor complications associated with these treatments. Preclinical models have also shown the potential for PDE1 inhibitors to address non-motor symptoms such as excessive daytime sleepiness, cognitive impairment and other non-motor symptoms. The Company has recently demonstrated the importance of ITI-214 and inhibition of PDE1 in reducing neuroinflammation and in regulating microglial function suggesting utility in treating neurodegenerative and neuropsychiatric disease.
About Parkinson’s Disease
Over 1.0 million and 1.2 million patients in
About the MDS-UPDRS
The Movement Disorder Society Unified Parkinson’s Disease Rating Scale MDS-UPDRS is a comprehensive 50 question assessment of both motor and non-motor symptoms associated with Parkinson's disease. The MDS-UPDRS has four parts: Part 1: non-motor experiences of daily living; Part 2: motor experiences of daily living: Part 3: motor examination; and Part 4: motor complications. Some sections require completion by patients and their caregivers and other completion by the clinician/investigator.
About
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the safety and efficacy of ITI-214; our clinical and nonclinical development plans for ITI-214, including our expectations concerning the timing of trials and studies and the availability of data; our beliefs about the potential uses and benefits of ITI-214; the potential of ITI-214 to address unmet needs in the treatment of Parkinson’s disease for improved motor control and potential disease modification and development efforts and plans under the caption "About Intra-Cellular Therapies." All such forward-looking statements are based on management's present expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to the following: our product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the
Contact:
Vice President, Corporate Communications and Investor Relations
646-440-9333
agray@burnsmc.com
212-213-0006
MEDIA INQUIRIES:
Corporate Media Relations, W2Owcg
pryan@wcgworld.com
Source: Intra-Cellular Therapies Inc.